New eye drug aims to save sight in wet AMD
NCT ID NCT06190093
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This trial tests whether an experimental drug called ONS-5010 (a form of bevacizumab) works as well as an approved drug, Lucentis, for treating wet age-related macular degeneration (AMD). Wet AMD causes rapid vision loss due to abnormal blood vessels leaking fluid in the eye. About 400 people with active wet AMD will receive injections of either ONS-5010 or Lucentis into the eye. The main goal is to see if ONS-5010 can prevent vision loss as effectively as Lucentis after 8 weeks of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bevacizumab (also called ONS-5010)
What this could lead to
If successful, this could offer a more affordable treatment option for wet age-related macular degeneration, helping preserve vision.
What could go wrong
This is a Phase 3 trial, so results are not yet confirmed. The drug may not prove as effective as Lucentis, and eye injections carry risks like infection or inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Site
Arcadia, California, 91006, United States
-
Clinical Site
Bakersfield, California, 93309, United States
-
Clinical Site
Beverly Hills, California, 90210, United States
-
Clinical Site
Huntington Beach, California, 92647, United States
-
Clinical Site
Laguna Hills, California, 92653, United States
-
Clinical Site
Long Beach, California, 90807, United States
-
Clinical Site
Modesto, California, 95356, United States
-
Clinical Site
Oakland, California, 94611, United States
-
Clinical Site
Pasadena, California, 91107, United States
-
Clinical Site
Poway, California, 92064, United States
-
Clinical Site
Sacramento, California, 95841, United States
-
Clinical Site
Colorado Springs, Colorado, 80909, United States
-
Clinical Site
Lakewood, Colorado, 80228, United States
-
Clinical Site
Waterford, Connecticut, 06385, United States
-
Clinical Site
Coral Springs, Florida, 33067, United States
-
Clinical Site
Fort Lauderdale, Florida, 33308, United States
-
Clinical Site
Jacksonville, Florida, 32216, United States
-
Clinical Site
Orlando, Florida, 32806, United States
-
Clinical Site
Stuart, Florida, 34994, United States
-
Clinical Site
Oak Forest, Illinois, 60452, United States
-
Clinical Site
Oak Park, Illinois, 03440, United States
-
Clinical Site
Carmel, Indiana, 46290, United States
-
Clinical Site
Lenexa, Kansas, 66215, United States
-
Clinical Site
Lexington, Kentucky, 40509, United States
-
Clinical Site
Hagerstown, Maryland, 21740, United States
-
Clinical Site
Edina, Minnesota, 55435, United States
-
Clinical Site
Saint Louis Park, Minnesota, 55416, United States
-
Clinical Site
Jackson, Mississippi, 39202, United States
-
Clinical Site
Teaneck, New Jersey, 07666, United States
-
Clinical Site
Albuquerque, New Mexico, 87109, United States
-
Clinical Site
Liverpool, New York, 13088, United States
-
Clinical Site
Oceanside, New York, 11572, United States
-
Clinical Site
Rochester, New York, 14620, United States
-
Clinical Site
Westbury, New York, 11590, United States
-
Clinical Site
Asheville, North Carolina, 28803, United States
-
Clinical Site
Hickory, North Carolina, 28602, United States
-
Clinical Site
Wake Forest, North Carolina, 27587, United States
-
Clinical Site
Winston-Salem, North Carolina, 27103, United States
-
Clinical Site
Edmond, Oklahoma, 73013, United States
-
Clinical Site
Charleston, South Carolina, 29414, United States
-
Clinical Site
Florence, South Carolina, 29501, United States
-
Clinical Site
Ladson, South Carolina, 29456, United States
-
Clinical Site
West Columbia, South Carolina, 29169, United States
-
Clinical Site
Rapid City, South Dakota, 57701, United States
-
Clinical Site
Germantown, Tennessee, 38138, United States
-
Clinical Site
Abilene, Texas, 79606, United States
-
Clinical Site
Arlington, Texas, 76012, United States
-
Clinical Site
Austin, Texas, 78705, United States
-
Clinical Site
Beaumont, Texas, 77707, United States
-
Clinical Site
Bellaire, Texas, 77401, United States
-
Clinical Site
Dallas, Texas, 75231, United States
-
Clinical Site
Round Rock, Texas, 78681, United States
-
Clinical Site
San Antonio, Texas, 78240, United States
-
Clinical Site
San Antonio, Texas, 78251, United States
-
Clinical Site
The Woodlands, Texas, 77384, United States
-
Clinical Site
Willow Park, Texas, 79606, United States
-
Clinical Site
Salt Lake City, Utah, 84107, United States
-
Clinical Site
Fairfax, Virginia, 22031, United States
-
Clinical Site
Lynchburg, Virginia, 24502, United States
-
Clinical Site
Bellevue, Washington, 98004, United States
-
Clinical Site
Silverdale, Washington, 98383, United States